AMAG Pharmaceuticals’ (AMAG) “Hold” Rating Reaffirmed at Cantor Fitzgerald

AMAG Pharmaceuticals (NASDAQ:AMAG)‘s stock had its “hold” rating reiterated by Cantor Fitzgerald in a research note issued on Wednesday. They presently have a $17.00 price target on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 22.30% from the company’s current price.

The analysts wrote, “Makena auto-injector is approved. AMAG announced today that the Makena auto-injector was approved. Although the PK data revealed a deficiency in the C max and AMAG disclosed that the FDA commented it would likely create a review issue, we suspect most investors believed the approval would occur.””

Other analysts also recently issued research reports about the company. Jefferies Group restated a “buy” rating and issued a $16.00 price target on shares of AMAG Pharmaceuticals in a research note on Sunday, November 5th. Janney Montgomery Scott restated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Monday, October 23rd. Zacks Investment Research downgraded AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Piper Jaffray Companies restated a “hold” rating and issued a $15.00 price target on shares of AMAG Pharmaceuticals in a research note on Thursday, January 18th. Finally, B. Riley restated a “hold” rating and issued a $16.00 price target on shares of AMAG Pharmaceuticals in a research note on Tuesday, January 16th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $19.44.

AMAG Pharmaceuticals (AMAG) traded up $0.20 during trading on Wednesday, hitting $13.90. The company had a trading volume of 1,025,248 shares, compared to its average volume of 1,001,212. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.59 and a quick ratio of 1.48. The stock has a market cap of $488.74, a P/E ratio of -2.29 and a beta of 0.79. AMAG Pharmaceuticals has a 52 week low of $11.93 and a 52 week high of $25.20.

A number of hedge funds have recently added to or reduced their stakes in AMAG. Bogle Investment Management L P DE bought a new position in AMAG Pharmaceuticals in the 4th quarter valued at approximately $4,352,000. State Street Corp lifted its position in AMAG Pharmaceuticals by 10.6% in the 2nd quarter. State Street Corp now owns 2,789,932 shares of the specialty pharmaceutical company’s stock valued at $51,336,000 after acquiring an additional 267,873 shares in the last quarter. Tocqueville Asset Management L.P. bought a new position in AMAG Pharmaceuticals in the 3rd quarter valued at approximately $3,958,000. Prudential Financial Inc. lifted its position in AMAG Pharmaceuticals by 35.7% in the 3rd quarter. Prudential Financial Inc. now owns 725,357 shares of the specialty pharmaceutical company’s stock valued at $13,382,000 after acquiring an additional 190,660 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in AMAG Pharmaceuticals by 18.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,215,249 shares of the specialty pharmaceutical company’s stock valued at $22,361,000 after acquiring an additional 189,576 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This article was first reported by American Banking News and is owned by of American Banking News. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/02/14/amag-pharmaceuticals-amag-hold-rating-reaffirmed-at-cantor-fitzgerald.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply